Broadly neutralizing anti-HIV-1 monoclonal antibodies in the clinic
M Caskey, F Klein, MC Nussenzweig - Nature medicine, 2019 - nature.com
Combination anti-retroviral therapy (ART) has revolutionized the treatment and prevention of
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …
HIV-1 infection. Taken daily, ART prevents and suppresses the infection. However, ART …
Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition
L Corey, PB Gilbert, M Juraska… - … England Journal of …, 2021 - Mass Medical Soc
Background Whether a broadly neutralizing antibody (bnAb) can be used to prevent human
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …
immunodeficiency virus type 1 (HIV-1) acquisition is unclear. Methods We enrolled at-risk …
Antibody 10-1074 suppresses viremia in HIV-1-infected individuals
Monoclonal antibody 10-1074 targets the V3 glycan supersite on the HIV-1 envelope (Env)
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
protein. It is among the most potent anti-HIV-1 neutralizing antibodies isolated so far. Here …
Effect of HIV antibody VRC01 on viral rebound after treatment interruption
KJ Bar, MC Sneller, LJ Harrison… - … England Journal of …, 2016 - Mass Medical Soc
Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …
Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge
N Pardi, AJ Secreto, X Shan, F Debonera… - Nature …, 2017 - nature.com
Monoclonal antibodies are one of the fastest growing classes of pharmaceutical products,
however, their potential is limited by the high cost of development and manufacturing. Here …
however, their potential is limited by the high cost of development and manufacturing. Here …
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
JP Casazza, EM Cale, S Narpala, GV Yamshchikov… - Nature medicine, 2022 - nature.com
Adeno-associated viral vector-mediated transfer of DNA coding for broadly neutralizing anti-
HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination …
HIV antibodies (bnAbs) offers an alternative to attempting to induce protection by vaccination …
A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges
Despite the success of potent anti-retroviral drugs in controlling human immunodeficiency
virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 …
virus type 1 (HIV-1) infection, little progress has been made in generating an effective HIV-1 …
Broadly neutralizing antibody treatment maintained HIV suppression in children with favorable reservoir characteristics in Botswana
RL Shapiro, G Ajibola, K Maswabi, M Hughes… - Science translational …, 2023 - science.org
Broadly neutralizing antibodies (bNAbs) may provide an alternative to standard antiretroviral
treatment (ART) for controlling HIV-1 replication and may have immunotherapeutic effects …
treatment (ART) for controlling HIV-1 replication and may have immunotherapeutic effects …
Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: a phase 1 open-label clinical trial in healthy adults
Background VRC01 is a human broadly neutralizing monoclonal antibody (bnMAb) against
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …
the CD4-binding site of the HIV-1 envelope glycoprotein (Env) that is currently being …